P- Reviewers Tosetti C, Amornyotin S S- Editor Wen LL L- Editor A E- Editor Xiong L
Published online Apr 28, 2013. doi: 10.3748/wjg.v19.i16.2507
Revised: February 5, 2013
Accepted: February 7, 2013
Published online: April 28, 2013
AIM: To investigate the prevalence of human leukocyte antigen (HLA) DQ2/8 alleles in Southern Italians with liver and gastrointestinal (GI) diseases outside of celiac disease.
METHODS: HLA DQ2/8 status was assessed in 443 patients from three ambulatory gastroenterology clinics in Southern Italy (University of Federico II, Naples, Loreto Crispi Hospital, Ruggi D’Aragona Hospital, Salerno). Patients were grouped based on disease status [pre-post transplant liver disease, esophageal/gastric organic and functional diseases, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)] and DQ2/8 alleles, which correspond to a celiac disease genetic risk gradient. Subject allele frequencies were compared to healthy Italian controls.
RESULTS: One hundred and ninety-six out of four hundred and forty-three (44.2%) subjects, median age 56 years and 42.6% female, were DQ2/8 positive. When stratifying by disease we found that 86/188 (45.7%) patients with liver disease were HLA DQ2/8 positive, 39/73 (53.4%) with functional upper GI diseases and 19/41 (46.3%) with organic upper GI diseases were positive. Furthermore, 38/105 (36.2%) patients with IBS and 14/36 (38.9%) with IBD were HLA DQ2/8 positive (P = 0.21). Compared to healthy controls those with functional upper GI diseases disorders had a 1.8 times higher odds of DQ2/8 positivity. Those with liver disease had 1.3 times the odds, albeit not statistically significant, of DQ2/8 positivity. Both those with IBS and IBD had a lower odds of DQ2/8 positivity compared to healthy controls.
CONCLUSION: The proportion of individuals HLA DQ2/8 positive is higher in those with liver/upper functional GI disease and lower in IBS/IBD as compared to general population estimates.
Citation: DiGiacomo D, Santonicola A, Zingone F, Troncone E, Caria MC, Borgheresi P, Parrilli G, Ciacci C. Human leukocyte antigen
DQ2/8prevalence in non-celiac patients with gastrointestinal diseases. World J Gastroenterol 2013; 19(16): 2507-2513
- URL: https://www.wjgnet.com/1007-9327/full/v19/i16/2507.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i16.2507
The human leukocyte antigen (HLA) class II genes comprise a highly polymorphic region in the short arm of chromosome 6 and are responsible for the creation of molecules involved in exogenous antigen presentation to T cells[1,2]. A subset of class II genes, encoding the DQ2 and DQ8 serotypes, have been frequently implicated in autoimmune disease pathogenesis. Prevalent in 30%-40% of healthy individuals, DQ2 and DQ8 are associated with diseases such as insulin-dependent diabetes mellitus and Hashimoto’s Thyroiditis[3,4]. These haplotypes may be best characterized through the gluten dependent relationship with celiac disease, an autoimmune mediated enteropathy affecting approximately 1% of Europeans and North Americans[5-7]. Consequently, many studies have attempted to estimate or infer the proportion of celiac disease risk due to particular DQ2/8 isoforms. For this reason, a genetic risk gradient has been recently characterized for DQ2/8 allele variants. The risk associated with celiac disease compared to those healthy depends, incrementally, on the number/type of HLA alleles possessed by an individual. Those with one or both of the DQ2/8 alleles have a risk ranging from 1:7-1:35, while those lacking all potential immunogenic loci have a near zero chance of contracting celiac disease[8,9]. Beyond celiac disease risk, disease severity and anti-tTg antibody levels are thought to be further tied to this disease/gene-dose relationship.
There are several reasons why it may be prudent to study DQ2/8 alleles in liver/gastrointestinal (GI) disease outside of celiac disease. First, evidence suggests that celiac disease may modify the risk of developing irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), eosinophilic esophagitis, or certain liver diseases[11-14]. Recent research has also shown the presence of HLA DQ2/8 alleles by themselves, outside of celiac disease, to be associated with GI disease[15-17]. This suggests that DQ2/8 haplotypes may act as a common factor in liver/GI disease pathogenesis; possibly through a similar mechanism to that of celiac disease. Furthermore, as DQ2/8 haplotypes contain myriad genes involved in inflammatory processes, such as tumor necrosis factor-α, causal mechanisms between these genes and GI disease may exist. Comparisons of DQ2/8 prevalence in non-celiac GI diseases, however have not been directly studied.
DQ2/8 associated disease risk is known to be modified across individuals or populations varying in ethnic background, geography or gender[19-23]. Moreover, DQ2/8 prevalence in Southern Italians has not been characterized. Thus, in this study we sought to first define the prevalence of HLA DQ2/8 alleles in a Southern Italy non-celiac GI tertiary ambulatory clinic population. Subsequently, we desired to determine what HLA DQ2/8 haplotypes, if any, were associated with specific liver/GI diseases.
Patients (n = 463) from the gastroenterology ambulatory clinics of three hospitals were recruited over a period of three months. Three hundred and twenty-two subjects were recruited from University of Federico II, Naples, Italy, 85 from Loreto Crispi Hospital, Naples, Italy and 56 from Ruggi D’Aragona Hospital, Salerno, Italy. During consultation patient’s demographics and disease history were recorded. Disease status was classified according to the nature of presenting problem. Separate categories were attributed generally to pre- or post-liver transplant treatment for chronic viral hepatitis, upper functional and organic GI (gastritis, esophagitis) diseases, lower functional (IBS) and lower inflammatory GI (IBD) diseases. Those with IBS were diagnosed via Rome III criteria. Overall population characteristics are described in Table 1. Participants were excluded from this study if they had missing data on disease status, multiple upper GI diseases or a prior diagnosis of celiac disease (n = 20).
|Overall||Liver||Upper functional||Upper organic||IBS||IBD|
Informed consent was obtained from each patient or patient guardian prior to study enrollment. The study was approved by ethics review board of the University of Naples “Federico II” and complied with the Helsinki II declaration.
Peripheral blood was collected in ethylene-diamino-tetra-acetic tubes and stored at 4 °C. Genomic DNA was isolated and polymerase chain reaction with sequence-specific primer was then performed to test solely for the presence/absence of DQ2/8 genes (Celiac Gene Screen, BioDiagene, Palermo, Italy). If patients were “susceptible to celiac disease”, further analysis was performed to discern specific alleles known to be associated with celiac disease risk (Celiac Gene Alleles, BioDiagene, Palermo, Italy). Fluorescence detection of DQ2/8 was performed using BioRun Reader (Celiac Gene Alleles, BioDiagene, Palermo, Italy). Patients “susceptible to celiac disease” are generally understood to have at least one of the HLA DQ2/8 alpha or beta alleles.
Using fluoro-immuno-assay, with human recombinant tTg as an antigen, patients positive for HLA DQ2/DQ8 alleles were tested for anti-tTg antibodies (a-tTg) and adequate immunoglobulin A (IgA) levels (CeliKey IgA, EliA, Phadia Freiburg, Germany). Anti-tissue transglutaminase levels greater than 10 (EliA U/mL) were considered positive. Those values between 7 and 10 (EliA U/mL) were considered equivocal and those less than 7 (EliA U/mL) negative. In later analysis both positive and equivocal groups were combined to increase power. None of the patients tested for total IgA were found to be deficient. Due to laboratory error several (n = 46) patients’ a-tTg levels were unattainable.
In order to compare the distribution of DQ2/8 alleles in study participants to the general Italian population we incorporated data from a prior published study by Megiorni et al. Healthy participants consisted of 292 healthy and 259 family based controls from Rome, Italy. The prevalence of DQ2.5/8 in healthy controls was 29%. This increased to 39% after incorporating the less common DQ2 isoforms.
DQ2 and DQ8 serotypes, if indicated, were tested for the following alleles: DQA1*0201, DQA1*03, DQA1*05, DQB1*02, DQB1*0301/0304 and DQB1*0302/0305. The following DR alleles were typed in order to determine the presence of DQ/DR haplotypes: DRB1*03, DRB1*04, DRB1*07, DRB1*11, DRB1*12.
DQ2/8 haplotypes were classified by Megiorni et al. DQ2 positivity was defined as DQA1*05 in cohort with DQB2*02 (DQ2.5), or DQA1*0201 (DQ2.2)/DQA1*03 (DQ2.3) with B1*02. DQ8 positivity was defined as DQA1*03 with DQB1*0302.
The Pearson χ2 test was performed on categorical data regarding demographics and the overall relationship of prevalence data. Fisher’s exact test was used for analysis of data with cell counts n < 5. Basic tabular analysis was also performed to obtain odds ratios. A cut-off of P = 0.05 was considered significant; all intervals were reported at 95% confidence. The analysis was performed using SAS 9.2 and SPSS 19.
We performed a cross-sectional analysis of HLA DQ2/8 allele prevalence in a Southern Italian population of patients afflicted with either liver or other digestive diseases outside of celiac disease. DQ2/8 haplotypes were stratified using a prior defined risk gradient relevant to celiac disease and prevalence in our disease population was compared to estimates in healthy controls.
From the patients included in our analysis, 196/443 (44.2%; 95%CI: 39.6%-48.9%) were considered to be HLA DQ2/8 positive, regardless of disease status. Within those who were positive 144/197 (73.1%) had DQ2.5 and/or DQ8. Table 2 details the prevalence of HLA DQ2/8 by age, gender and GI disease in the study’s participants. The overall difference in DQ2/8 prevalence between these disease groups was not statistically significant (P = 0.21).
|Proportion of positive subjects||Prevalence||P value|
Subjects DQ2/8 alleles were organized highest to lowest genetic risk of celiac disease, as described in Megiorni et al and compared to healthy controls. No statistically significant difference in HLA DQ2/8 prevalence between our subject population and healthy controls was found (P = 0.16). As with healthy controls, study subjects clustered towards lower celiac disease risk DQ2/8 alleles with DQ2.5 heterozygotes lying in the majority. Odds ratio calculations revealed that those with functional gastric/esophageal disorders had a 1.8 fold higher odds of being HLA DQ2/8 positive as compared to healthy controls. Patients with organic gastric/esophageal disorders had 1.3 higher odds of DQ2/8 positivity as compared to healthy controls. The odds were also increased in the liver disease group and decreased in IBS/IBD groups although these values were not significant (Table 3).
|Disease group||Odds ratio||95%CI|
Out of the patients with a-tTg data available no a-tTg positive patients were found in the liver disease/transplant and inflammatory bowel group. One out of sixty-four (1.54%) subjects with functional gastric/esophageal issues and 4/90 (4.26%) with lower functional syndrome were found to be positive (P = 0.04; Table 4).
The clinical importance of HLA genetic testing has been established in several diseases[3,24]. In this study we performed a cross-sectional analysis on a Southern Italian population with the goal of investigating the prevalence of several HLA DQ2/8 serotypes in those with GI issues outside of celiac disease.
HLA DQ2/8 prevalence in Italy is thought to be between 30% and 40%, although this estimate may vary by geographic subpopulation[8,24]. Nearly half of the subjects in this study (44%) were considered HLA DQ2/8 positive. A lesser proportion of those with IBS/IBD were HLA DQ2/8 positive although these differences were not significant (P = 0.21) (Table 2). Within those who were HLA DQ2/8 positive the majority possessed low risk celiac disease alleles (Table 5). Thus, our results suggest that DQ2/8 haplotypes may play a role in liver/digestive disease through pathological mechanisms different from those of celiac disease.
|DQ2 and DQ8||2 (0.45)||1 (0.2)||1:45|
|DQ2, β1*02/*02||17 (3.8)||13 (2.4)||1:63|
|DQ8, β1*02 positive||8 (1.8)||4 (0.7)||1:39|
|β2, β1*02/*02||11 (2.5)||2 (0.4)||1:16|
|DQ2, β1*02/X||85 (19.2)||106 (19.2)||1:100|
|DQ8, β1*02 negative||32 (7.2)||36 (6.5)||1:90|
|β2, β1*02/X||41 (9.3)||53 (9.7)||1:104|
|α5 + other||247 (55.8)||336 (60.9)||1:101|
Several studies have established significant associations between DQ2, primary sclerosing cholangitis and hepatitis C virus recurrence after transplant[25,26]. The large proportion (46%) of DQ2/8 positive viral hepatitis patients in our study population agrees with the hypothesis that these haplotypes may be involved in certain liver disease pathogenesis.
Differentiating between functional and organic GI disease can be difficult yet is important due to the impacts on clinical decision-making. In this study we stratified our patient population based on upper and lower functional or organic GI disorders. Several studies have directly compared DQ2/8 haplotype prevalence in upper organic GI disease. Lucendo et al previously demonstrated a null association between DQ2/8 and eosinophilic esophagitis. Interestingly, DR3 and DR4 have been significantly linked with atrophic gastritis in a similar Italian population. The positive yet non-significant relationship between our organic gastric/esophageal patients and DQ2/8 may be a consequence of the various upper GI organic diseases captured in our patient population. Unfortunately, due to sample size restrictions, we were not able to stratify by specific disease. Ultimately these findings suggest that it may be inappropriate to generalize upper organic GI disease as one confluent group because it is unknown whether the lack of a significant association was truly due to causal or confounding disease factors.
Functional GI disorders represent the majority of GI cases yet many have etiologies, which are poorly understood. Whether it is genetic abnormalities, psychological factors or other environmental variables, functional disorders can represent complex, difficult to solve cases. The strongest evidence of an association with DQ2/8 in this study was found in patients with functional upper GI disorders. Patients in this study had 1.8 higher odds of DQ2/8 positivity if they had an upper functional GI disorder as compared to healthy controls. This may signify that the risk of functional upper GI onset or recurrence is modified by the presence of particular DQ2/8 haplotypes. Currently, the only published data, which could be used to comment on these findings, relates to celiac disease and DQ2/8. For example, Ford et al conducted a meta-analysis, which found no association between celiac disease and functional dyspepsia. Overall, it is too early to decide whether DQ2/8 could be used to differentiate functional vs organic disease or at least be incorporated into a clinical algorithm that dictates likelihood of disease.
Known immunological associations between IBD and DR7, which is linked to both DQ2 and DQ8 haplotypes have been established[17,30]. Prior prevalence data though suggests that IBD, particularly Crohn’s disease, is lower in individuals with the DQ2/8 linked celiac disease. The relative modest prevalence of IBD (39%) in our study supports this notion. IBS has also been linked to HLA DQ2/8 haplotypes and bowel transit speeds[16,31]. Additionally several studies have demonstrated that those with IBS and DQ2/8 positivity tend to present with symptoms indicative of gluten sensitivity and are responsive to a gluten-free diet[31,32]. Out of all of the disease groupings those with IBS had the lowest prevalence of DQ2/8 positivity (36%). As those on a gluten-free diet were excluded from this study this may account for the low prevalence DQ2/8 positivity in those with IBS.
A small part of this study wished to obtain a baseline level of a-tTg positive patients in a previously diagnosed GI population (Table 4). If these patients were assumed to have celiac disease, these results correspond with known prevalence estimates of the disease.
Those who had prior diagnosed celiac disease or were adhering to a gluten-free diet were excluded from the study. It is thought to be common for patients with general abdominal pain, diarrhea and/or nausea to experiment with a gluten-free diet in an attempt to ameliorate symptoms. As such, removing individuals who may have experimented with this type of diet eliminated a potentially large source of bias. An additional strength of this study was the precision with which HLA haplotypes and disease types were measured. Barring laboratory error, the HLA typing assays in this study have been shown to have near perfect sensitivity and specificity. During blood collection patient’s disease status was recorded. Thus, it was also unlikely that the classification of disease was subject to recall bias.
This study aimed to generally define HLA DQ2/8 prevalence in diseases/disorders that may be linked to celiac disease. As such there were several limitations, which could have potentially biased the results. The cross-sectional nature limited the collection of subject’s lifestyle and disease history. Therefore, data such as age of disease onset and severity were unavailable. The Southern Italian population is typically generically and environmentally homogenous thus unmeasured confounders would not significantly influence the results. Controls from the study were described as “healthy”. We know from Megiorni et al that these participants did not have celiac disease but it is possible they were afflicted with a liver or GI disease. This type of bias would have most likely pushed the magnitude of our estimates towards the null, masking potential associations. The small sample size in our study also limited our ability to make statistically significant conclusions and investigate specific DQ2/8 allele associations.
Due to the limitations of the present study it may be difficult to make truly suggestive conclusions regarding the relationship between HLA DQ2/8 positive patients and liver/GI conditions. This study though has taken the first step through implying a potential association between specific HLA DQ2/8 alleles and GI disease pathogenesis. Reproducibility of these results may eventually lead to the creation of clinical markers of elusive disease onset, such as in IBS or other clinically ambiguous disorders[11,16,28,35,36]. Future studies should involve expanding the number of study participants in order to look at specific DQ2 alleles or investigating the shared influence of non-HLA celiac disease risk alleles.
The authors are grateful to BioDiagene, Palermo, Italy and Phadia S.r.l Freiburg, Germany, which supplied products for the laboratory testing. We would also like to thank Columbia University’s Mailman School of Public Health Travel Fund for providing assistance to defray travel costs to Federico II where the work for this paper was performed and Dr. Ryan Demmer at the Mailman School of Public Health, Department of Epidemiology for his expertise during review of the manuscript. A final thank you to Drs. Paolo Andreozzi and Cristina Bucci at Federico II for their assistance with data collection and sorting.
Human leukocyte antigen (HLA) DQ2/8 alleles and associated haplotypes are important players in the pathogenesis of several autoimmune diseases, particularly celiac disease. The distribution of DQ2/8 alleles in gastrointestinal (GI) disease outside of celiac disease though has been poorly established.
HLA DQ2/8 alleles in patients can be easily tested with currently laboratory capabilities. Knowledge of HLA DQ2/8 frequencies related to autoimmune disease is being used to identify high risk populations and drive clinical recommendations regarding DQ2/8 gene testing.
Similar studies have described HLA DQ2/8 risk alleles in diseases such as type 1 diabetes or celiac disease. For example, in celiac disease those with one or more of the DQ2.5/8 alleles are at highest risk of disease onset. To date no studies have directly compared DQ2/8 prevalence in GI disease outside of celiac disease. By comparing the prevalence of HLA DQ2/8 to that of healthy controls we demonstrated that, like celiac disease, those with liver disease and esophageal/gastric disorders (both organic and functional) are more likely to be DQ2/8 positive.
Although this study is preliminary in nature, the results suggest that the development of novel clinical susceptibility markers of GI disease may exist. Particular DQ2/8 polymorphisms may point to increased risk of certain liver or esophageal/gastric disease.
The study investigated the prevalence of HLA DQ2/8 alleles in Southern Italians with liver and GI diseases outside of celiac disease. The proportion of individuals HLA DQ2/8 positive resulted higher in those with liver/gastric or esophageal GI disease and lower in irritable bowel syndrome/inflammatory bowel disease as compared to general population estimates. The study is well designed and conduced.
|1.||Bergseng E, Sidney J, Sette A, Sollid LM. Analysis of the binding of gluten T-cell epitopes to various human leukocyte antigen class II molecules. Hum Immunol. 2008;69:94-100. [PubMed] [DOI]|
|2.||Gebe JA, Swanson E, Kwok WW. HLA class II peptide-binding and autoimmunity. Tissue Antigens. 2002;59:78-87. [PubMed]|
|3.||Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57:1084-1092. [PubMed] [DOI]|
|4.||Kokaraki G, Daniilidis M, Yiangou M, Arsenakis M, Karyotis N, Tsilipakou M, Fleva A, Gerofotis A, Karadani N, Yovos JG. Major histocompatibility complex class II (DRB1*, DQA1*, and DQB1*) and DRB1*04 subtypes’ associations of Hashimoto’s thyroiditis in a Greek population. Tissue Antigens. 2009;73:199-205. [PubMed] [DOI]|
|5.||Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, Murray L, Metzger MH, Gasparin M, Bravi E. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42:587-595. [PubMed] [DOI]|
|6.||Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010;7:204-213. [PubMed] [DOI]|
|7.||Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, Hill ID. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163:286-292. [PubMed] [DOI]|
|8.||Megiorni F, Mora B, Bonamico M, Barbato M, Nenna R, Maiella G, Lulli P, Mazzilli MC. HLA-DQ and risk gradient for celiac disease. Hum Immunol. 2009;70:55-59. [PubMed] [DOI]|
|9.||Wolters VM, Wijmenga C. Genetic background of celiac disease and its clinical implications. Am J Gastroenterol. 2008;103:190-195. [PubMed] [DOI]|
|10.||Karinen H, Kärkkäinen P, Pihlajamäki J, Janatuinen E, Heikkinen M, Julkunen R, Kosma VM, Naukkarinen A, Laakso M. Gene dose effect of the DQB1*0201 allele contributes to severity of coeliac disease. Scand J Gastroenterol. 2006;41:191-199. [PubMed] [DOI]|
|11.||El-Salhy M, Lomholt-Beck B, Gundersen D. The prevalence of celiac disease in patients with irritable bowel syndrome. Mol Med Rep. 2011;4:403-405. [PubMed] [DOI]|
|12.||Casella G, D’Incà R, Oliva L, Daperno M, Saladino V, Zoli G, Annese V, Fries W, Cortellezzi C. Prevalence of celiac disease in inflammatory bowel diseases: An IG-IBD multicentre study. Dig Liver Dis. 2010;42:175-178. [PubMed] [DOI]|
|13.||Leeds JS, Höroldt BS, Sidhu R, Hopper AD, Robinson K, Toulson B, Dixon L, Lobo AJ, McAlindon ME, Hurlstone DP. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol. 2007;42:1214-1220. [PubMed] [DOI]|
|14.||Lucendo AJ, Arias Á, Pérez-Martínez I, López-Vázquez A, Ontañón-Rodríguez J, González-Castillo S, De Rezende LC, Rodrigo L. Adult patients with eosinophilic esophagitis do not show an increased frequency of the HLA-DQ2/DQ8 genotypes predisposing to celiac disease. Dig Dis Sci. 2011;56:1107-1111. [PubMed] [DOI]|
|15.||Albayrak A, Ertek M, Tasyaran MA, Pirim I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey. Biochem Genet. 2011;49:258-269. [PubMed] [DOI]|
|16.||Vazquez-Roque MI, Camilleri M, Carlson P, McKinzie S, Murray JA, Brantner TL, Burton DD, Zinsmeister AR. HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2011;23:481-487. [PubMed] [DOI]|
|17.||Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. MHC Class II alleles in ulcerative colitis-associated colorectal cancer. Gut. 2009;58:1226-1233. [PubMed]|
|18.||Koskela RM, Karttunen TJ, Niemelä SE, Lehtola JK, Ilonen J, Karttunen RA. Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. Eur J Gastroenterol Hepatol. 2008;20:276-282. [PubMed] [DOI]|
|19.||Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res. 2011;39:D1171-D1176. [PubMed] [DOI]|
|20.||Buhler S, Sanchez-Mazas A. HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One. 2011;6:e14643. [PubMed] [DOI]|
|21.||Megiorni F, Mora B, Bonamico M, Barbato M, Montuori M, Viola F, Trabace S, Mazzilli MC. HLA-DQ and susceptibility to celiac disease: evidence for gender differences and parent-of-origin effects. Am J Gastroenterol. 2008;103:997-1003. [PubMed] [DOI]|
|22.||Salamon H, Klitz W, Easteal S, Gao X, Erlich HA, Fernandez-Viña M, Trachtenberg EA, McWeeney SK, Nelson MP, Thomson G. Evolution of HLA class II molecules: Allelic and amino acid site variability across populations. Genetics. 1999;152:393-400. [PubMed]|
|23.||Guerini FR, Fusco C, Mazzi B, Favoino B, Nocera G, Agliardi C, Ceresa D, Valentino M, Mininni D, Zanzottera M. HLA-Cw allele frequencies in northern and southern Italy. Transpl Immunol. 2008;18:286-289. [PubMed] [DOI]|
|24.||Bourgey M, Calcagno G, Tinto N, Gennarelli D, Margaritte-Jeannin P, Greco L, Limongelli MG, Esposito O, Marano C, Troncone R. HLA related genetic risk for coeliac disease. Gut. 2007;56:1054-1059. [PubMed] [DOI]|
|25.||Audet M, Piardi T, Cag M, Navarro F, Ornis S, Cinqualbre J, Wolf P, Panaro F. Hepatitis C recurrence after liver transplantation: has the human leukocyte antigen mismatching at individual loci a role? J Gastroenterol Hepatol. 2011;26:1772-1778. [PubMed]|
|26.||Boberg KM, Spurkland A, Rocca G, Egeland T, Saarinen S, Mitchell S, Broomé U, Chapman R, Olerup O, Pares A. The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scand J Gastroenterol. 2001;36:886-890. [PubMed] [DOI]|
|27.||Lahner E, Spoletini M, Buzzetti R, Corleto VD, Vannella L, Petrone A, Annibale B. HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Dig Liver Dis. 2010;42:854-859. [PubMed] [DOI]|
|28.||Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491. [PubMed] [DOI]|
|29.||Ford AC, Ching E, Moayyedi P. Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. Aliment Pharmacol Ther. 2009;30:28-36. [PubMed] [DOI]|
|30.||Puglisi F, Capuano P, Simone M, Verzillo F, Laurentaci C, Catalano G. Immunogenetics of inflammatory bowel disease. Minerva Gastroenterol Dietol. 1999;45:5-9. [PubMed]|
|31.||Wahnschaffe U, Schulzke JD, Zeitz M, Ullrich R. Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5:844-850; quiz 769. [PubMed] [DOI]|
|32.||Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology. 2001;121:1329-1338. [PubMed]|
|33.||Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, Kaukinen K, Rostami K, Sanders DS, Schumann M. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13. [PubMed] [DOI]|
|34.||Megiorni F, Mora B, Bonamico M, Nenna R, Di Pierro M, Catassi C, Drago S, Mazzilli MC. A rapid and sensitive method to detect specific human lymphocyte antigen (HLA) class II alleles associated with celiac disease. Clin Chem Lab Med. 2008;46:193-196. [PubMed] [DOI]|
|35.||Cash BD, Rubenstein JH, Young PE, Gentry A, Nojkov B, Lee D, Andrews AH, Dobhan R, Chey WD. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-1193. [PubMed] [DOI]|